Penn Pharma Showcases High Potency Facility

Penn Pharma will be meeting with professionals at the world’s leading pharmaceutical networking event CPhI Worldwide. The team at Penn Pharma will be meeting potential clients and business contacts to share the latest industry trends in the ever changing pharmaceutical market.  

It comes as the company, based in Tredegar, Blaenau Gwent, south Wales, launches a new £14 million high-tech facility, purpose-built to develop and manufacture tablets and capsules containing highly potent compounds, built in response to market need.  

Richard Yarwood, Penn Pharma’s Chief Executive Officer, said: “We are very much looking forward to showcasing our world leading facility at CPhI, which has been designed to cater for the growing range of potent compounds requiring contained manufacturing processes.  

“We will be able to discuss the design of our facility, including the cutting-edge technology and machinery. This includes the highly contained equipment trains designed to minimise the need for personal protective equipment (PPE).  

“Our investment in the new facility further shows our commitment to the industry and enables us to meet the evolving needs of our clients globally. We’re excited to be attracting more and more clients from around the world who can see the quality and reliability of what we are able to now offer.”  

Penn Pharma delivers integrated drug development, clinical trial supply and manufacturing services to the international healthcare industry.

Stand 42K45

Penn Pharmaceutical Services Ltd, +44 1495 711 222, www.pennpharm.co.uk.